juli
volum
issu
virus
formid
target
drug
develop
oblig
intracellular
parasit
take
host
cellular
machineri
agenda
seem
understand
intim
work
cellular
pathway
better
seek
develop
treatment
diffi
cult
inactiv
viru
without
harm
host
cell
past
decad
concert
effort
control
hiv
aid
epidem
antivir
drug
come
target
viral
protein
pathway
uniqu
viral
life
cycl
becom
possibl
interfer
viral
infect
replic
virus
without
unaccept
host
cell
toxic
howev
antivir
drug
develop
hand
virus
none
antivir
drug
complet
effect
viral
resist
sequenc
divers
drug
toxic
signifi
cant
problem
antivir
therapi
articl
discuss
recent
progress
obstacl
har
rna
interfer
prevent
treat
viral
infect
hepat
b
c
viru
infect
respons
signifi
cant
global
epidem
moreov
treatment
acut
viral
infect
includ
one
caus
hemorrhag
fever
enceph
death
prospect
global
pandem
caus
newli
emerg
infect
sar
coronaviru
avian
infl
uenza
set
econom
develop
chang
ecolog
made
rapid
develop
novel
antivir
therapi
intern
prioriti
surpris
soon
rna
interfer
rnai
discov
work
mammalian
cell
research
hone
attempt
har
ancient
antivir
mechan
prevent
treat
viral
infect
rnai
use
small
doublestrand
rna
silenc
gene
bear
complementari
sequenc
although
endogen
gene
silenc
oper
multipl
mechan
includ
mrna
cleavag
inhibit
translat
epigenet
modifi
cation
chromatin
mrna
cleavag
effi
cient
mechan
mechan
har
antivir
therapi
small
rna
either
exogen
small
interf
rna
sirna
endogen
microrna
taken
cytoplasm
rnainduc
silenc
complex
risc
cleav
one
strand
leav
remain
unpair
guid
strand
search
mrna
bear
complementari
sequenc
recogn
target
site
mrna
nearli
perfect
complementar
guid
sirna
mrna
cut
argonaut
endonucleas
risc
degrad
silenc
express
protein
encod
typic
protein
express
reduc
complet
elimin
rnai
derek
dykxhoorn
judi
lieberman
fund
write
articl
support
grant
nation
institut
health
grant
jl
nation
institut
health
play
role
prepar
essay
jl
declar
pend
patent
applic
use
rna
interfer
target
hiv
infect
fa
apoptot
proinfl
ammatori
gene
activ
respons
infect
topic
applic
small
interf
rna
use
microbicid
antivir
prevent
treatment
indic
celltypespecifi
c
small
interf
rna
deliveri
use
antibodi
fragmentprotamin
fusion
protein
research
translat
discuss
health
intervent
context
translat
basic
clinic
research
clinic
evid
practic
figur
organ
lack
adapt
immun
respons
pathogen
rnai
import
defens
viral
infect
one
strategi
analog
suppress
silenc
exhibit
plant
virus
elabor
protein
infl
uenza
vaccinia
bind
inactiv
doublestrand
rna
anoth
strategi
employ
adenoviru
copiou
express
microrna
bind
inactiv
microrna
export
dicer
process
machineri
mammalian
virus
also
take
advantag
rnai
carri
replic
strategi
particular
sever
herpesvirus
encod
microrna
seem
involv
regul
viral
latenc
virus
may
use
microrna
regul
sequenti
pattern
gene
express
much
like
organ
use
microrna
regul
key
gene
determin
progress
one
development
state
anoth
microrna
direct
cleavag
earli
transcript
encod
antigen
hepat
c
viru
make
use
microrna
effi
cientli
express
liver
cell
match
sequenc
viral
untransl
region
promot
replic
sinc
virus
evolv
exploit
intrins
host
molecular
pathway
promot
replic
import
tool
probe
microrna
regul
gene
express
even
uninfect
cell
interf
either
viral
encod
host
microrna
requir
effi
cient
viral
replic
may
provid
novel
strategi
antivir
therapeut
recent
studi
show
feasibl
inhibit
microrna
function
vivo
use
cholesterolconjug
sirna
rnai
use
suppress
viral
replic
target
either
viral
gene
host
gene
need
viral
replic
silenc
viral
gene
viral
polymeras
master
regul
viral
gene
transcript
essenti
fundament
viral
process
silenc
viral
gene
act
earli
viral
life
cycl
may
effect
suppress
viral
replic
target
late
gene
accessori
viral
gene
contribut
pathogenesi
vital
viral
replic
vitro
studi
shown
use
rnai
replic
fi
gure
show
possibl
target
suppress
hiv
replic
silenc
prevent
viral
entri
viral
gene
also
silenc
interfer
viral
product
sirna
could
also
target
viral
long
term
repeat
even
provir
genom
rna
prior
integr
although
whether
done
controversi
target
multipl
gene
enhanc
viral
suppress
reduc
chanc
viral
escap
sequenc
mutat
vitro
suppress
virtual
everi
class
viru
whether
viru
use
doublestrand
singleposit
negativestrand
rna
dna
genom
algorithm
sirna
short
hairpin
rna
shrna
design
provid
guidanc
design
effect
sequenc
process
imperfect
success
rate
algorithm
predict
sequenc
effect
silenc
target
gene
predict
sequenc
maxim
viral
inhibit
minim
sequencespecifi
c
offtarget
effect
aris
unintend
silenc
partial
homolog
gene
sequencespecifi
c
bind
tolllik
receptor
trigger
infl
ammatori
respons
best
candid
sirna
sequenc
need
determin
experi
offtarget
silenc
gene
partial
homolog
imposs
avoid
inhibit
translat
may
involv
complementar
sevennucleotid
stretch
sirna
howev
translat
inhibit
gener
small
impact
gene
express
minim
avoid
sequenc
target
import
gene
unlik
import
impedi
clinic
use
rnai
although
clinic
signifi
cant
toxic
offtarget
effect
diffi
cult
predict
advanc
offtarget
effect
caus
incorpor
passeng
strand
instead
antisens
strand
sirna
risc
avoid
design
sirna
end
favor
risc
uptak
intend
activ
strand
import
obstacl
use
rnai
activ
principl
antivir
treatment
relat
issu
viral
sequenc
divers
potenti
viral
escap
gene
silenc
sequenc
mutat
rna
virus
polioviru
hiv
may
particularli
suscept
escap
mutat
low
fi
deliti
genom
replic
problem
circumv
silenc
host
gene
requir
viral
entri
replic
howev
target
host
gene
may
lead
unaccept
host
cell
toxic
unless
rnai
select
induc
infect
cell
transient
vulner
subset
cell
might
achiev
target
sirna
exclus
vulner
cell
regul
express
shrna
use
induc
promot
activ
viral
gene
product
recent
strategi
use
antibodi
fragment
fusion
protein
bind
deliv
sirna
cell
bear
cell
surfac
receptor
recogn
antibodi
deliv
sirna
silenc
gene
express
specifi
calli
hivinfect
cell
express
shrna
design
silenc
host
protein
requir
hiv
replic
might
induc
upon
hiv
infect
use
tatdepend
promot
hiv
infect
viral
coreceptor
might
except
host
gene
silenc
without
toxic
sinc
individu
homozyg
genet
mutat
function
inactiv
complet
asymptomat
sinc
morbid
mortal
associ
mani
viral
infect
may
secondari
stereotyp
overli
exuber
infl
ammatori
immun
respons
silenc
host
gene
proxim
pathway
provid
anoth
possibl
type
intervent
exampl
hepat
b
c
cytopath
virus
trigger
hepat
activ
immun
cell
express
fasl
infi
ltrate
liver
infect
upregul
death
receptor
fa
hepatocyt
make
prime
target
immunemedi
apoptosi
silenc
fa
hepatocyt
fasl
immun
cell
might
provid
effect
immunemodul
therapi
circumv
chronic
liver
cell
damag
b
intranas
intratrach
administr
sirna
either
mix
lipid
protect
respiratori
infect
mice
c
intranas
administr
sirna
rhesu
macaqu
protect
sar
coronaviru
infect
intraven
inject
sirna
incorpor
special
liposom
inhibit
hepat
b
viru
replicon
e
intracerebr
inject
sirna
protect
fl
aviviru
enceph
herp
simplex
viru
type
hbv
hepat
b
viru
hcv
hepat
c
viru
rsv
respiratori
syncyti
viru
viral
gene
target
relat
problem
viral
sequenc
divers
potenti
escap
mutat
circumv
choos
highli
conserv
sequenc
whose
mutat
might
result
impair
viral
fi
tness
may
possibl
even
highli
divers
mutationpron
viru
like
hiv
mani
short
sequenc
conserv
even
nucleotid
level
target
highli
conserv
hiv
vif
sequenc
research
abl
suppress
varieti
primari
viral
isol
chosen
random
repres
fi
distinct
viral
clade
recent
studi
kumar
colleagu
publish
plo
medicin
sequenc
conserv
among
varieti
fl
avivirus
silenc
japanes
enceph
viru
west
nile
viru
anoth
approach
prevent
viral
escap
mutat
combin
sirna
target
multipl
gene
much
effect
drug
therapi
hiv
requir
combin
antivir
drug
target
differ
step
hiv
replic
enceph
virus
kumar
colleagu
studi
suggest
might
possibl
administ
cocktail
sirna
could
effect
suppress
varieti
like
suspect
virus
defi
nitiv
diagnosi
made
thu
avoid
danger
delay
treatment
particular
viru
cocktail
sirna
target
viral
host
gene
whose
product
act
differ
point
viral
life
cycl
like
act
synergist
suppress
viral
replic
effect
henc
reduc
chanc
viral
escap
mutat
howev
cellular
rnai
machineri
limit
capac
sinc
silenc
suppress
excess
irrelev
doublestrand
small
rna
strategi
use
adenoviru
suppress
rnai
similarli
gene
therapi
vector
express
high
amount
shrna
caus
toxic
interf
nuclear
export
endogen
microrna
therefor
probabl
limit
number
sirna
effect
incorpor
treatment
howev
publish
studi
yet
defi
ned
limit
key
obstacl
har
rnai
treatment
get
small
rna
cytoplasm
cell
vivo
accomplish
either
fi
gure
way
introduc
small
rna
cell
small
molecul
drug
sirna
use
plasmid
viral
vector
encod
shrna
process
like
endogen
microrna
precursor
small
molecul
approach
best
suit
shortterm
intervent
gene
therapi
potenti
use
longterm
silenc
via
express
integr
transgen
treat
chronic
infect
hiv
hepat
c
gene
therapi
strategi
may
make
sens
howev
concern
safeti
control
gene
express
make
gene
therapi
less
practic
immedi
applic
although
small
rna
taken
cell
bodi
mucos
tissu
bodi
import
except
sirna
mix
cation
lipid
even
effi
cientli
taken
epitheli
cell
lung
vagina
figur
genit
tract
sirna
taken
deep
lamina
propria
underli
stroma
mechan
uptak
understood
viral
infect
transmit
mucos
surfac
provid
opportun
interven
prevent
treat
viral
infect
transmiss
acut
infect
mice
local
instil
sirna
target
viral
gene
shown
strike
protect
respiratori
challeng
infl
uenza
parainfl
uenza
respiratori
syncyti
virus
potenti
sirna
treat
viral
infect
also
shown
primat
challeng
sar
coronaviru
encourag
anim
experi
led
recent
fi
rst
phase
studi
sirna
design
treat
viral
infect
studi
begin
test
potenti
rnai
treatment
acut
respiratori
syncyti
viru
infect
lead
caus
death
seriou
morbid
newborn
children
anoth
mucos
tissu
sirna
shown
prevent
viral
infect
femal
genit
tract
sirna
target
gene
protect
mice
lethal
infect
sirna
penetr
deep
cervicovagin
tissu
silenc
persist
nine
day
mice
even
protect
sirna
administr
delay
hour
viral
challeng
studi
suggest
possibl
persist
antivir
state
might
achiev
genit
tract
prevent
sexual
transmiss
reactiv
even
oncogenesi
varieti
sexual
transmit
virus
hiv
human
papillomaviru
topic
applic
antivir
sirna
might
also
effect
local
access
site
viral
infect
upper
respiratori
tract
eye
ie
herp
kerat
skin
ie
wart
although
therapeut
deliveri
sirna
silenc
clearli
feasibl
mucos
surfac
system
treatment
virus
dissemin
infect
tissu
deep
within
bodi
diffi
cult
challeng
effi
cientli
transduc
cell
vivo
main
impedi
system
uptak
diffi
culti
travers
cell
membran
short
halflif
intraven
inject
sirna
sever
potenti
solut
former
problem
describ
recent
includ
coval
conjug
passeng
sirna
strand
celltarget
moieti
noncoval
associ
sirna
celltarget
molecul
incorpor
sirna
liposom
nanoparticl
short
halflif
caus
rapid
renal
fi
ltration
endogen
ribonucleas
digest
readili
address
incorpor
sirna
complex
particl
minor
chemic
modifi
cation
rna
backbon
earli
studi
show
inhibit
hepat
viral
replic
requir
introduc
sirna
via
highvolum
bolu
term
hydrodynam
inject
caus
rightsid
heart
failur
suitabl
clinic
use
although
sirna
effect
introduc
organ
liver
kidney
select
catheter
princip
vein
drain
tissu
invas
costli
similarli
intracerebr
juli
volum
issu
key
obstacl
har
rnai
treatment
get
small
rna
cytoplasm
cell
vivo
inject
approach
use
deliv
sirna
target
fl
avivirus
like
use
clinic
intraven
lowpressur
inject
chemic
modifi
ed
sirna
incorpor
modifi
ed
liposom
reduc
replic
hepat
b
viru
replicon
mice
studi
fi
rst
demonstr
system
antivir
effect
use
method
inject
clinic
feasibl
like
approach
develop
system
sirna
deliveri
describ
also
work
silenc
viral
infect
howev
far
achiev
noninvas
method
introduc
sirna
brain
would
need
treat
viral
enceph
remain
elus
goal
